Electroacupuncture  ||| S:0 E:19 ||| JJ
inhibits  ||| S:19 E:28 ||| JJ
inflammatory  ||| S:28 E:41 ||| JJ
injury  ||| S:41 E:48 ||| NN
by  ||| S:48 E:51 ||| IN
targeting  ||| S:51 E:61 ||| VBG
the  ||| S:61 E:65 ||| DT
miR‑9‑mediated  ||| S:65 E:80 ||| FW
NF‑κB  ||| S:80 E:86 ||| FW
signaling  ||| S:86 E:96 ||| FW
pathway  ||| S:96 E:104 ||| FW
following  ||| S:104 E:114 ||| FW
ischemic  ||| S:114 E:123 ||| FW
stroke  ||| S:123 E:130 ||| FW
The  ||| S:130 E:134 ||| DT
aim  ||| S:134 E:138 ||| NN
of  ||| S:138 E:141 ||| IN
the  ||| S:141 E:145 ||| DT
present  ||| S:145 E:153 ||| JJ
study  ||| S:153 E:159 ||| NN
was  ||| S:159 E:163 ||| VBD
to  ||| S:163 E:166 ||| TO
investigate  ||| S:166 E:178 ||| VB
the  ||| S:178 E:182 ||| DT
neuroprotective  ||| S:182 E:198 ||| JJ
mechanism  ||| S:198 E:208 ||| NN
of  ||| S:208 E:211 ||| IN
the  ||| S:211 E:215 ||| DT
miR‑9‑mediated  ||| S:215 E:230 ||| JJ
activation  ||| S:230 E:241 ||| NN
of  ||| S:241 E:244 ||| IN
the  ||| S:244 E:248 ||| DT
nuclear  ||| S:248 E:256 ||| JJ
factor  ||| S:256 E:263 ||| NN
( ||| S:263 E:264 ||| -LRB-
NF ||| S:264 E:266 ||| NNP
) ||| S:266 E:267 ||| -RRB-
‑κB  ||| S:267 E:271 ||| VBP
signaling  ||| S:271 E:281 ||| VBG
pathway  ||| S:281 E:289 ||| NN
by  ||| S:289 E:292 ||| IN
electroacupuncture  ||| S:292 E:311 ||| NNS
( ||| S:311 E:312 ||| -LRB-
EA ||| S:312 E:314 ||| NNP
)  ||| S:314 E:316 ||| -RRB-
stimulation  ||| S:316 E:328 ||| NN
of  ||| S:328 E:331 ||| IN
the  ||| S:331 E:335 ||| DT
Quchi  ||| S:335 E:341 ||| NNP
( ||| S:341 E:342 ||| -LRB-
LI11 ||| S:342 E:346 ||| NNP
)  ||| S:346 E:348 ||| -RRB-
and  ||| S:348 E:352 ||| CC
Zusanli  ||| S:352 E:360 ||| NNP
( ||| S:360 E:361 ||| -LRB-
ST36 ||| S:361 E:365 ||| NNP
)  ||| S:365 E:367 ||| -RRB-
acupoints  ||| S:367 E:377 ||| NN
in  ||| S:377 E:380 ||| IN
a  ||| S:380 E:382 ||| DT
rat  ||| S:382 E:386 ||| JJ
model  ||| S:386 E:392 ||| NN
of  ||| S:392 E:395 ||| IN
middle  ||| S:395 E:402 ||| JJ
cerebral  ||| S:402 E:411 ||| JJ
artery  ||| S:411 E:418 ||| NN
occlusion  ||| S:418 E:428 ||| NNS
( ||| S:428 E:429 ||| -LRB-
MCAO ||| S:429 E:433 ||| NNP
) ||| S:433 E:434 ||| -RRB-
.  ||| S:434 E:436 ||| .
The  ||| S:436 E:440 ||| DT
present  ||| S:440 E:448 ||| JJ
study  ||| S:448 E:454 ||| NN
demonstrated  ||| S:454 E:467 ||| VBN
that  ||| S:467 E:472 ||| IN
EA  ||| S:472 E:475 ||| NNP
alleviated  ||| S:475 E:486 ||| VBD
the  ||| S:486 E:490 ||| DT
symptoms  ||| S:490 E:499 ||| NNS
of  ||| S:499 E:502 ||| IN
neurological  ||| S:502 E:515 ||| JJ
deficits  ||| S:515 E:524 ||| NNS
and  ||| S:524 E:528 ||| CC
reduced  ||| S:528 E:536 ||| VBD
the  ||| S:536 E:540 ||| DT
infarct  ||| S:540 E:548 ||| JJ
volume  ||| S:548 E:555 ||| NN
in  ||| S:555 E:558 ||| IN
the  ||| S:558 E:562 ||| DT
rat  ||| S:562 E:566 ||| JJ
brains ||| S:566 E:572 ||| NNS
.  ||| S:572 E:574 ||| .
The  ||| S:574 E:578 ||| DT
expression  ||| S:578 E:589 ||| NN
of  ||| S:589 E:592 ||| IN
miR‑9 in  ||| S:592 E:601 ||| CD
the  ||| S:601 E:605 ||| DT
peri‑infarct  ||| S:605 E:618 ||| CD
cortex  ||| S:618 E:625 ||| NNS
was  ||| S:625 E:629 ||| VBD
increased  ||| S:629 E:639 ||| VBN
in  ||| S:639 E:642 ||| IN
the  ||| S:642 E:646 ||| DT
EA  ||| S:646 E:649 ||| NNP
group  ||| S:649 E:655 ||| NN
compared  ||| S:655 E:664 ||| VBN
with  ||| S:664 E:669 ||| IN
the  ||| S:669 E:673 ||| DT
MCAO  ||| S:673 E:678 ||| NNP
group ||| S:678 E:683 ||| NN
,  ||| S:683 E:685 ||| ,
and  ||| S:685 E:689 ||| CC
the  ||| S:689 E:693 ||| DT
expression  ||| S:693 E:704 ||| NN
of  ||| S:704 E:707 ||| IN
NF‑κB  ||| S:707 E:713 ||| CD
signaling  ||| S:713 E:723 ||| CD
pathway‑associated  ||| S:723 E:742 ||| CD
factors ||| S:742 E:749 ||| NNS
,  ||| S:749 E:751 ||| ,
NF‑κB  ||| S:751 E:757 ||| NNP
p65 ||| S:757 E:760 ||| NNP
,  ||| S:760 E:762 ||| ,
tumor  ||| S:762 E:768 ||| NN
necrosis  ||| S:768 E:777 ||| NN
factor  ||| S:777 E:784 ||| NN
( ||| S:784 E:785 ||| -LRB-
TNF ||| S:785 E:788 ||| NNP
) ||| S:788 E:789 ||| -RRB-
‑α  ||| S:789 E:792 ||| NNP
and  ||| S:792 E:796 ||| CC
interleukin  ||| S:796 E:808 ||| NNS
( ||| S:808 E:809 ||| -LRB-
IL ||| S:809 E:811 ||| NNP
) ||| S:811 E:812 ||| -RRB-
‑1β  ||| S:812 E:816 ||| NNP
were  ||| S:816 E:821 ||| VBD
reduced ||| S:821 E:828 ||| VBN
.  ||| S:828 E:830 ||| .
Notably ||| S:830 E:837 ||| RB
,  ||| S:837 E:839 ||| ,
miR‑9 inhibitors  ||| S:839 E:856 ||| NNP
were  ||| S:856 E:861 ||| VBD
revealed  ||| S:861 E:870 ||| VBN
to  ||| S:870 E:873 ||| TO
have  ||| S:873 E:878 ||| VB
the  ||| S:878 E:882 ||| DT
ability  ||| S:882 E:890 ||| NN
to  ||| S:890 E:893 ||| TO
suppress  ||| S:893 E:902 ||| VB
EA‑alleviated  ||| S:902 E:916 ||| CD
cerebral  ||| S:916 E:925 ||| CD
inflammation  ||| S:925 E:938 ||| NNS
and  ||| S:938 E:942 ||| CC
the  ||| S:942 E:946 ||| DT
expression  ||| S:946 E:957 ||| NN
of  ||| S:957 E:960 ||| IN
NF‑κB  ||| S:960 E:966 ||| CD
downstream‑related  ||| S:966 E:985 ||| CD
factors ||| S:985 E:992 ||| NNS
,  ||| S:992 E:994 ||| ,
NF‑κB  ||| S:994 E:1000 ||| NNP
p65 ||| S:1000 E:1003 ||| NNP
,  ||| S:1003 E:1005 ||| ,
TNF‑α  ||| S:1005 E:1011 ||| NNP
and  ||| S:1011 E:1015 ||| CC
IL‑1β ||| S:1015 E:1020 ||| NNP
,  ||| S:1020 E:1022 ||| ,
and  ||| S:1022 E:1026 ||| CC
caused  ||| S:1026 E:1033 ||| VBD
no  ||| S:1033 E:1036 ||| DT
alteration  ||| S:1036 E:1047 ||| NN
on  ||| S:1047 E:1050 ||| IN
the  ||| S:1050 E:1054 ||| DT
level  ||| S:1054 E:1060 ||| NN
of  ||| S:1060 E:1063 ||| IN
NF‑κB  ||| S:1063 E:1069 ||| CD
upstream‑related  ||| S:1069 E:1086 ||| CD
protein  ||| S:1086 E:1094 ||| NN
inhibitor  ||| S:1094 E:1104 ||| NN
of  ||| S:1104 E:1107 ||| IN
κBα ||| S:1107 E:1110 ||| NNP
,  ||| S:1110 E:1112 ||| ,
suggesting  ||| S:1112 E:1123 ||| VBG
that  ||| S:1123 E:1128 ||| IN
the  ||| S:1128 E:1132 ||| DT
cerebral  ||| S:1132 E:1141 ||| JJ
protective  ||| S:1141 E:1152 ||| JJ
efficacy  ||| S:1152 E:1161 ||| NN
of  ||| S:1161 E:1164 ||| IN
EA  ||| S:1164 E:1167 ||| NNP
targets  ||| S:1167 E:1175 ||| FW
miR‑9‑mediated  ||| S:1175 E:1190 ||| FW
NF‑κB  ||| S:1190 E:1196 ||| FW
downstream  ||| S:1196 E:1207 ||| FW
pathway  ||| S:1207 E:1215 ||| FW
following  ||| S:1215 E:1225 ||| FW
ischemic  ||| S:1225 E:1234 ||| FW
stroke ||| S:1234 E:1240 ||| FW
.  ||| S:1240 E:1242 ||| .
